Datasets of Systemic Immune-Inflammation Index in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy to Predict One-Year Survival

The Systemic Immune Inflammation Index (SII), a non-invasive biomarker utilizing platelet, neutrophil, and lymphocyte counts, serves as an objective and predictive indicator for the comprehensive assessment of host immune status and inflammation in non-small cell lung cancer (NSCLC) patients. Its use has demonstrated superior prognostic value compared to traditional markers. This dataset included a total of 65 advanced-stage NSCLC patients who underwent a chemotherapy response assessment after receiving a minimum of three cycles of chemotherapy from January 2020 to December 2022 at Dr. M Djamil Hospital Padang. The survival duration is defined as the period (measured in months) from the initiation of therapy until the patient either passes away or completes the observation phase. The last follow-up was in December 2023. Survival is categorized into two groups: one with a survival period of less than one year and the other with a duration equal to or exceeding one year. The SII optimal cut-off values for one-year survival were obtained through a receiver operating characteristic (ROC) curve analysis. Data analysis was performed using IBM version 25.0. The results emphasize the strength of the predictive model, with a remarkable Area Under the Curve (AUC) value of 0.745 (95% CI 0.62-0.87). According to the ROC analysis, the ideal cutoff for the SII to forecast one-year survival was determined to be 1760.00 x 10^9/L with a sensitivity of 74% and specificity of 81%. The study's robust findings on the SII as a prognostic marker for one-year survival in advanced-stage NSCLC patients provide a compelling opportunity for researchers, especially in the Indonesian population. As the initial dataset in the country, further exploration of SII's clinical utility is warranted to validate and enhance its predictive capabilities in similar contexts.